The new innovation imperative: reshaping biopharma business models

Technological, economic, competitive and consumer-driven pressures are forcing fundamental changes in how pharmaceutical and biotechnology (“biopharma”) firms and companies do business.

The buyers of their products are changing. The products themselves are changing. And the nature, and number, of their competitors is changing too. These external and internal pressures are shifting how value is defined in the pharmaceutical industry, as well as how it’s captured — and by whom.

View the full report.